文献速递脊柱关节炎

儿童关节炎与风湿病研究联盟注册中幼年脊柱关节炎特征:高生物制剂使用、低HLA-B27阳性率及骶髂关节炎性别分布均衡

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该研究基于CARRA注册数据库,描述了902例附着点炎相关关节炎(ERA)和幼年银屑病关节炎(PsA)患儿的特征。结果显示ERA患儿诊断年龄更大、男性更多,HLA-B27阳性率在ERA组为38%、PsA组为12%;72%的ERA患儿和64%的PsA患儿至少使用过一种生物制剂;骶髂关节炎见于28%的患儿,其中54%为女性、36%为HLA-B27阳性、81%使用过生物制剂。

要点

  • ERA患儿中HLA-B27阳性率仅38%,骶髂关节炎患儿中仅36%阳性。
  • 骶髂关节炎患儿中女性占54%,性别分布均衡。
  • 72%的ERA患儿和81%的骶髂关节炎患儿至少使用过一种生物制剂。

核心结论

  • 在该注册中,ERA或幼年PsA患儿超过900例,生物制剂使用率高,尤其在骶髂关节炎患儿中。
  • 骶髂关节炎患儿中性别分布均衡,女性占54%。

研究设计与样本

  • 基于儿童关节炎与风湿病研究联盟(CARRA)注册的队列研究,纳入902例ERA或幼年PsA患儿。
  • 描述人口学特征、临床特征和治疗,并比较有无骶髂关节炎的患儿。

主要发现

  • ERA患儿诊断年龄为10.8岁,幼年PsA为8.2岁(P < 0.01);ERA组男性占56%,PsA组占38%(P < 0.01)。
  • 多关节受累在ERA中占57%,在幼年PsA中占72%。
  • HLA-B27阳性率在ERA组为38%,在幼年PsA组为12%。
  • 至少使用过一种生物制剂的比例在ERA组为72%,在幼年PsA组为64%。
  • 骶髂关节炎(临床和/或影像学诊断)见于28%的患儿(ERA中40%,幼年PsA中12%),其中54%为女性、36%为HLA-B27阳性、81%至少使用过一种生物制剂。

关键数值与推荐

  • 在骶髂关节炎患儿中,首次临床活动性骶髂关节炎就诊时的医生整体疾病活动度评分、家长/患者整体健康状况评分和临床幼年关节炎疾病活动度评分10均显著差于无活动性骶髂关节炎的首次就诊。

临床怎么用

  • 对于ERA或幼年PsA患儿,应关注高生物制剂使用需求,尤其合并骶髂关节炎者。
  • 骶髂关节炎患儿中女性比例较高且HLA-B27阳性率低,提示不能仅凭HLA-B27或性别排除骶髂关节炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA) who were enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. METHODS: All children with ERA and those with juvenile PsA were identified. Demographic characteristics, clinical characteristics, and treatments were described. The children with sacroiliitis and those without sacroiliitis were compared. In the children with sacroiliitis, the first visit with clinically active sacroiliitis (which came first in 72% of cases) was compared to the first visit without clinically active sacroiliitis. RESULTS: A total of 902 children with ERA or juvenile PsA were identified. Children with ERA were older at diagnosis (ages 10.8 years versus 8.2 years; P < 0.01) and were more likely to be male (56% versus 38%; P < 0.01). Polyarticular involvement was reported in 57% of children with ERA and in 72% of those with juvenile PsA. Of the children tested, HLA-B27 was positive in 38% of those in the ERA group and in 12% of those in the juvenile PsA group. At least 1 biologic was taken by 72% of those with ERA and 64% of those with juvenile PsA. Sacroiliitis (diagnosed clinically and/or by imaging) was reported in 28% of the children (40% of those with ERA and 12% of those with juvenile PsA). Of these, 54% of the children were female, 36% were HLA-B27 positive, and 81% took at least 1 biologic. In children with sacroiliitis, scores according to the physician global assessment of disease activity, parent/patient global assessment of well-being, and clinical Juvenile Arthritis Disease Activity Score 10 were all significantly worse at the first visit with clinically active sacroiliitis versus the first visit without active sacroiliitis. CONCLUSION: In this registry, there are more than 900 children with ERA or juvenile PsA. There was high biologic use in this population, especially in those with sacroiliitis. Further, there was equal sex representation in those children with sacroiliitis.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Rumsey DG, Lougee A, Matsouaka R, et al. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care Res (Hoboken). 2021. PMID: 33331139. doi:10.1002/acr.24537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。